cholangio-

cholangio-

, cholangi- [Gr. cholē, bile + Gr. angeion, vessel]
Prefixes meaning bile vessel.
References in periodicals archive ?
Immunohistochemical (IHC) Profile of Epithelioid Hemangioendothelioma and Differential Diagnoses IHC and Epithelioid Special Stains Hemangioendothelioma Angiosarcoma Cholangio- carcinoma Factor VIII + + - CD31 + + - CD34 + + - D2-40 + [+ or -] - Pan-cytokeratin 6 - + HepPar-1 - - - Mucicarmine - ([+ or -] in - + early lesions) IHC and Hepatocellular Metastatic Special Stains Carcinoma Carcinoma Factor VIII - - CD31 - - CD34 [+ or -] (sinusoidal - capillarization) D2-40 - Pan-cytokeratin [+ or -] + HepPar-1 + - Mucicarmine - [+ or -] Abbreviations: +, positive staining;-, negative staining; [+ or -], variably expressed.
Isomoto, "Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing," Digestion, vol.
(a) Other tumors: adrenal cortical neoplasm (n = 24), breast ductal carcinoma (n = 110), breast lobular carcinoma (n = 31), cholangio- carcinoma (n = 11), embryonal carcinoma (n = 24), esophageal adenocarcinoma (n = 30), gastric carcinoma (n = 21), hepatocellular carcinoma (n = 18), lung adenocarcinoma (n = 50), lung small cell carcinoma (n = 49), pancreatic carcinoma (n = 50), prostatic carcinoma (n = 100), seminoma (n = 30), urothelial carcinoma (n = 83), and yolk sac tumor (n = 12).
Magnetic resonance cholangio- pancreatography versus endoscopic retrograde cholangio- pancreatography in the diagnosis of common bile duct stones: a prospective comparative study.
Study, dose Cholangio- Hepatocellular Gingival (ng/kg) (a) carcinoma adenoma CKE SCC TCDD (TEF = 1.0) 0 0 (b) ** 0 ** 0 ** 2.5 ** 3 0 0 0 5.7 10 0 0 0 2.6 22 2.9 0 0 0 46 10.3 2.6 0 10.2 100 54.9 ** 29.9 ** 21.1 ** 22.0 ** PCB-126 (TEF = 0.1) 0 0 ** 3.2 ** 0 ** 0 ** 30 0 5.2 0 2.6 100 2.5 2.5 0 2.5 175 0 0 0 2.7 300 13.6 * 5.5 2.7 5.4 550 14.0 * 9.7 26.0 ** 4.7 1,000 60.3 ** 20.9 * 83.5 ** 20.2 ** PeCDF /TEF = 0.5) 0 0 * 2.4 ** 0 2.4 6 0 0 0 5.2 20 0 2.7 0 2.7 44 2.6 0 0 0 92 2.8 5.5 0 2.8 200 5.4 10.9 2.7 8.1 TEF mixture (c) 0 0 ** 0 ** 0 ** 2.7 10 0 2.5 0 2.5 22 4.8 2.4 0 0 46 17.4 2.5 5.1 0 100 26.0 ** 31.0 ** 54.7 ** 6.0 (a) Animals were treated with each compound or a mixture with each respective dose, 5 days/week for up to 104 weeks (n= 53-55/group).